Amy Garabedian, J.D. has extensive global and diversified legal and team building experience. During her more than 15 years practicing law, she has advised pharmaceutical & biotech companies from start-ups to multi-national public companies on the complex legal issues facing industry today.  Ms. Garabedian most recently served as associate general counsel of Spark Therapeutics (Roche), where she served as a strategic and innovative advisor, playing an instrumental role in the successful U.S. launch of the first gene therapy for a genetic disease, led key business development transactions, and enabled pre-clinical, clinical and commercial product development.  Earlier in her career, Ms. Garabedian held positions of increasing responsibility at Sandoz (Novartis) and as a business and finance attorney at Ballard Spahr LLP.   She holds a bachelor of science degree in genetics and developmental biology from Penn State University, a master of science degree in regulatory affairs from Temple University and a juris doctor degree from Widener University Delaware School of Law.